Full-Time

Market Access Analytics and Insights Associate Director

US Market Access, Data and Analytics

Posted on 9/4/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$164k - $246k/yr

+ Bonus + Equity Awards

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid

Hybrid-Eligible: work remotely up to two days per week.

Category
Consulting (1)
Required Skills
Power BI
SQL
Data Analysis
Snowflake
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree in quantitative discipline required (e.g., Engineering, Statistics, Economics, Finance)
  • 7-10 years of experience in the pharmaceutical or biotech industry, 6+ years of insights, analytics and reporting is required
  • 10+ years of US pharmaceutical industry experience with increasing responsibilities
  • 5+ years of experience in developing US Market Access preferably in Access Strategy, Pricing, Reimbursements and Chargebacks, Value Proposition in an analytical role
  • Excellent working knowledge of the Market Access data sets including MMIT, IQVIA, Pricing / GTN (Model-N), Trade and Distribution (IntegriChain 852/867), Dispenses and Claims (IQVIA, Optum) and Real-World Data (DRG, Market Scan, etc.)
  • Exceptional analytics and technical data query skills with experience creating and/or supporting complex analytics and working closely with data scientists and engineers
  • Strong to expert proficiency in Power BI and SQL is a must. Working knowledge of data lake platforms such as Snowflake is a plus
  • Stakeholder management: Ability to communicate confidently and succinctly to senior leaders and ability to manage complexity and ambiguity in a highly matrixed environment
  • Strong data story telling skills with Powerpoint, Excel, and PowerBI; ability to distill complex information synthesized into concise and impactful visuals, messages and presentations
  • Demonstrated ability to lead initiatives that require cross collaboration across multiple functional areas
  • Flexible, adaptable, diplomatic, and able to effectively deal with ambiguity
  • Ability to influence decision-makers through incisive analysis and persuasive communication, including experience in working with senior leadership to support financial forecasting and analytics, and/or commercial launch planning
Responsibilities
  • Lead the delivery of therapeutic area specific analytical insights in response to market access landscape, issues and trends
  • Cross-Collaborate with the Global Commercial Insights and Analytics Organization to incorporate qualitative and quantitative market research into market access analytics and strategy development
  • Partner with GPS (Guidance & Patient Services) to integrate insights related to compliance, persistence, and adherence into access analytics and patient journey understanding
  • Translate business objectives into analytic requirements to support Market Access Strategy enablement, delivering insights into payer policy trends, formulary positioning, and value messaging strategies across both commercial and government payers
  • Conduct value and access outcomes analyses to evaluate policy impact, coverage variation, and access risks for pipeline, launch, and in-line brands
  • Support Gross-to-Net (GTN) planning by supplying payer mix insights, utilization controls, and contract execution data to improve forecast inputs and sensitivity modeling
  • Generate actionable insights using advanced data tools and technologies—SQL, PowerBI, Excel, and other BI platforms—while ensuring data validation, clarity, and business relevance
  • Build executive-ready dashboards and insight products that communicate access opportunities and barriers through compelling, data-driven narratives tailored to senior and cross-functional stakeholders
  • Demonstrate strong data storytelling skills by synthesizing technical data into clear and strategic business recommendations that drive decision-making and access execution
  • Work directly with payer account and Payer Field Engagement teams to translate insights into pull-through strategies and support tactical alignment across payer engagements
  • Leverage strong knowledge of Veeva systems to connect access insights to field execution and account planning processes
  • Analyze Trade & Distribution data, including 852/867 feeds (e.g., IntegriChain), to support visibility into product availability, distribution channel behavior, and downstream market access implications
  • Understand the impact of utilization management, tiering and formulary or medical policy impact on overall demand, use of therapeutic alternatives and co-pay support
  • Conduct investigative analytics to validate and/or quantify market access-related phenomenon related to competitive or customer tactics. Identify through quantitative methods, value drivers that guide options to remove barriers to access and improve brand value proposition
  • Perform claims analysis and identify market dynamics that demonstrate the impact of payer controls and build models to portray risks, opportunities and sensitivities
  • Conduct proactive research and analysis of various data sources, digestion of industry publications and engagement of internal/external stakeholders to define channel, segment and payer mix
  • Inform and support future pre- and post- contract evaluations with contract operations and administration teams. This may include volume and geographic considerations as well as utilization management trends
  • Act as a connector between Access Strategy and internal data partners, aligning business questions with data architecture and insight delivery roadmaps
  • Serve as an advocate in integrating market access insights sourced across Vertex teams – Market Access Strategy, Govt. Pricing, Trade Operations, Distribution and Field teams; develop strong partnerships with DTE (Data Technology & Engineering), DSS (Data Strategy & Solutions) and HEOR teams in support of market access goals
Desired Qualifications
  • Master’s Degree in a quantitative discipline and/or MBA, MPH
  • An entrepreneurial spirit and ability to proactively develop creative solutions to complex problems
  • Good understanding of state and federal policies and government programs such as 340B impacting market access, trade, distribution, and gross-to-net impacts
  • Good understanding of statutory government pricing methodologies
  • 6 or more years of pharmaceutical manufacturer market access experience and subject matter expertise with Health Plans, PBMs, Hospital Systems, Specialty Pharmacies and Healthcare Policy stakeholders
  • Highly diverse US product launch experience across different disease areas, specially rare diseases, strongly preferred
  • Experience analyzing large data sets, such as transactional or claims data, using a statistical analysis software package (e.g., R, Python, etc. a plus)
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hits $2.96B, up 12% from strong CF demand.
  • Hypercon deal with Halozyme enables at-home subcutaneous delivery.
  • CASGEVY expands to UAE via Yas Clinic on March 31, 2026.

What critics are saying

  • VX-264 diabetes therapy halts after Phase 1/2 C-peptide failure March 28.
  • VX-993 pain drug fails Phase 2 primary endpoint in Q2 2026.
  • CSO Altshuler retires August 2026, leaving 6-month research vacuum.

What makes Vertex Pharmaceuticals unique

  • Vertex dominates cystic fibrosis with Trikafta and ALYFTREK modulators.
  • CASGEVY delivers first CRISPR/Cas9 gene therapy for sickle cell.
  • JOURNAVX pioneers NaV1.8 inhibition for acute pain approval.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Investing.com
Apr 13th, 2026
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026.

Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026. Published 04/13/2026, 06:16 AM (C) Reuters. Investing.com - Bank of America has reaffirmed Argenx (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) as its top large-cap biotech picks for 2026, with price targets of $1,013 and $598, respectively. For Argenx, BofA cited strong commercial performance of Vvygart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, driven by expansion into earlier treatment lines and growing real-world experience. The firm highlighted upcoming phase 3 results for efgartigimod in myositis in the third quarter and empasiprubart in multifocal motor neuropathy in the fourth quarter as potential catalysts. For Vertex, BofA emphasized the strength of the cystic fibrosis franchise in providing cash flow to support pipeline expansion. The firm identified the rare kidney disease franchise as a key long-term growth driver, noting positive data for povetacicept in IgA nephropathy. Among commercial small- and mid-cap picks, BofA selected KalVista Pharmaceuticals (NASDAQ:KALV) with a $32 price target and Rhythm Pharmaceuticals (NASDAQ:RYTM) with a $149 price target. KalVista's Ekterly was approved in July 2025 as the first on-demand hereditary angioedema therapy, while Rhythm's Imcivree became the first approved therapy for acquired hypothalamic obesity in March. For pre-commercial small- and mid-cap stocks, BofA named Ocular Therapeutix (NASDAQ:OCUL) with a $27 price target and Bicara Therapeutics (NASDAQ:BCAX) with a $35 price target as top picks. Should you invest $2,000 in VRTX right now? ProPicks AI evaluates VRTX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if VRTX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

National Today
Apr 11th, 2026
Fiduciary Alliance buys $2.2M stake in Vertex Pharmaceuticals

Fiduciary Alliance LLC purchased 4,828 shares of Vertex Pharmaceuticals during the fourth quarter, valued at approximately $2.19 million, according to a recent 13F filing with the Securities and Exchange Commission. The investment reflects confidence in the Boston-based biotechnology company, which specialises in developing treatments for serious diseases, particularly cystic fibrosis. Vertex's portfolio of CFTR modulators has transformed standards of care for many CF patients. Vertex's share price has risen over 20% in the past year as the company continues expanding its cystic fibrosis treatments and exploring new therapeutic areas. The investment signals institutional interest in Vertex's growth potential and drug pipeline.

GlobalData
Apr 8th, 2026
Halozyme and Vertex sign deal for Hypercon technology.

Halozyme and Vertex sign deal for Hypercon technology. Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments. Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's Hypercon technology. Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics, aiming to reduce injection volume and facilitate at-home administration for patients. Vertex will make an upfront payment of $15m to Halozyme, along with potential future milestone payments. Halozyme will also receive royalties on net sales of any products that are developed using the technology. Halozyme Therapeutics president and CEO Helen Torley said: "This collaboration with Vertex underscores the versatility and potential of its Hypercon technology to enable small volume, patient-delivered next generation biologics. "Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases." Halozyme's Enhanze drug delivery technology, based on the enzyme rHuPH20, supports the subcutaneous administration of injected drugs and fluids to lower treatment burden and enhance convenience. Enhanze has been involved in over one million patient lives through ten commercialised products across more than 100 countries, and is licensed to companies such as AbbVie, Eli Lilly, Pfizer, Roche, Takeda, and ViiV Healthcare. Halozyme has expanded its drug delivery portfolio to include Hypercon, as well as Surf Bio's polymer-based hyperconcentration technology, broadening the possibilities for subcutaneous biologics delivery. In January 2026, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter's Enhanze drug delivery technology. Give your business an edge with its leading industry insights.

The Pharma Letter
Apr 8th, 2026
Halozyme inks license agreement with Vertex.

Halozyme inks license agreement with Vertex. 8 April 2026 San Diego, USA-based Halozyme Therapeutics (Nasdaq: HALO) late yesterday announced it has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (Nasdaq: VRTX). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 17 November 2025 25 April 2025 14 September 2017 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 8 April 2026 7 April 2026 Company spotlight. A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases characterized by abnormal appetite and metabolic disorders. More features in pharmaceutical. 8 April 2026 7 April 2026

UAE News.Net
Mar 31st, 2026
Abu Dhabi records major healthcare milestones in Q1 2026, reinforcing global leadership.

Abu Dhabi records major healthcare milestones in Q1 2026, reinforcing global leadership. WAM 31 Mar 2026, 19:06 GMT+ ABU DHABI, 31st March, 2026 (WAM) - The Emirate of Abu Dhabi has achieved a series of significant medical and scientific milestones during the first quarter of 2026, reflecting the rapid advancement of its healthcare ecosystem and reinforcing its position as a regional and global hub for medical innovation and advanced therapies. Supported and overseen by the Department of Health - Abu Dhabi, and in collaboration with leading healthcare institutions and global partners, Yas Clinic Khalifa City, in cooperation with the Abu Dhabi Stem Cells Center and Vertex Pharmaceuticals, successfully administered the UAE's first gene-editing therapy for haemoglobin disorders using "CASGEVY," based on CRISPR/Cas9 technology, marking a groundbreaking national achievement. Sheikh Khalifa Medical City also recorded a medical milestone by performing the UAE's first cardiac biopsy on a paediatric patient following a heart transplant, as part of the visiting physicians programme, further enhancing specialised healthcare services within the country. Cleveland Clinic Abu Dhabi achieved several pioneering procedures, including the UAE's first breast reconstruction surgery using the Deep Inferior Epigastric Perforator (DIEP) flap with robotic assistance for a breast cancer survivor. The hospital also conducted robotic-assisted stereoelectroencephalography (SEEG), representing a major advancement in diagnosing and treating complex epilepsy cases. Additionally, it performed the first remote robotic-assisted nephroureterectomy between the UAE and Pakistan, highlighting significant progress in robotic surgery and expanding access to advanced care. The hospital further carried out the first basivertebral nerve ablation using the "Intracept" procedure in the Middle East and North Africa, marking a notable development in pain management. PureLab, a subsidiary of PureHealth Group, in collaboration with LOD Autonomous, launched a pilot project to transport blood samples via drones between Sheikh Khalifa Medical City and its Abu Dhabi facility, enhancing laboratory efficiency and accelerating sample delivery. Burjeel Medical City inaugurated the Burjeel Eye Institute, managed by Emirati professionals, alongside the launch of the Advanced Sarcoma and Bone Tumour Centre in collaboration with Burjeel Orthopaedic Institute. In a significant scientific breakthrough, the group also announced the discovery of a previously undocumented rare genetic disorder, "El-Hattab-Schmidts syndrome," affecting brain development and muscle strength, opening new avenues for innovative gene therapies for children. The city also launched the Abu Dhabi Neuro-Oncology Centre, in collaboration with Burjeel Cancer Institute and the Neuroscience Institute, to provide comprehensive and advanced care for patients across all age groups. Sheikh Shakhbout Medical City introduced an advanced treatment option involving implantable hypoglossal nerve stimulation for obstructive sleep apnoea in adults, improving patients' quality of life. The hospital also adopted video-assisted thoracoscopic surgery (VATS), including uniportal sympathectomy, performed through a small concealed incision, reducing pain, accelerating recovery, and improving cosmetic outcomes. The Department of Health - Abu Dhabi launched the UAE's first clinical trial for the treatment of retinitis pigmentosa linked to the MerTK gene, using an innovative gene therapy developed by Opus Genetics, reflecting the emirate's commitment to advanced solutions for rare diseases. In another medical achievement, a specialised team at Corniche Hospital successfully diagnosed a rare case of partial anomalous pulmonary venous drainage (PAPVD) in a newborn at an early stage, improving treatment outcomes and preventing complications. Meanwhile, a medical team at Madinat Zayed Hospital in Al Dhafra successfully treated a complex renal condition using advanced interventional radiology techniques, demonstrating the efficiency of medical cadres and the continuous development of healthcare services across the emirate.

INACTIVE